1. Academic Validation
  2. Niclosamide: Beyond an antihelminthic drug

Niclosamide: Beyond an antihelminthic drug

  • Cell Signal. 2018 Jan;41:89-96. doi: 10.1016/j.cellsig.2017.04.001.
Wei Chen 1 Robert A Mook Jr 2 Richard T Premont 2 Jiangbo Wang 2
Affiliations

Affiliations

  • 1 Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States. Electronic address: w.chen@duke.edu.
  • 2 Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States.
Abstract

Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide. However recent studies have indicated that niclosamide may have broad clinical applications for the treatment of diseases other than those caused by parasites. These diseases and symptoms may include Cancer, Bacterial and viral Infection, metabolic diseases such as Type II diabetes, NASH and NAFLD, artery constriction, endometriosis, neuropathic pain, rheumatoid arthritis, sclerodermatous graft-versus-host disease, and systemic sclerosis. Among the underlying mechanisms associated with the drug actions of niclosamide are uncoupling of Oxidative Phosphorylation, and modulation of Wnt/β-catenin, mTORC1, STAT3, NF-κB and Notch signaling pathways. Here we provide a brief overview of the biological activities of niclosamide, its potential clinical applications, and its challenges for use as a new therapy for systemic diseases.

Keywords

Bacterial and viral infection; Cancer; Lupus; Metabolic diseases; NAFLD; NASH; Neuropathic pain; Niclosamide; Rheumatoid arthritis; Sclerodermatous graft-versus-host disease; Systemic sclerosis; Type II diabetes.

Figures
Products